Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity in a real-world survey of certain US patients. Medicare patients who took ...

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) shares jumped early trading Thursday, the stock's best move in a month after fresh data showed Ozempic delivered better outcomes than ...

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity.

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity. Stream ...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations that it would do a better job of preventing heart attacks and strokes than its older medicine Trulicity.

Mounjaro (tirzepatide) led to greater weight loss and better glucose control than high doses of Trulicity (dulaglutide), according to a study published April 4 in Annals of Internal Medicine. A common ...

An analysis of FDA's reporting system for adverse events turned up three dozen cases of acute gallbladder disease in patients taking glucagon-like peptide-1 (GLP-1) receptor agonists for diabetes or ...

Trulicity (dulaglutide) is not a weight loss drug, but people receiving it may lose weight. Higher doses of Trulicity typically result in more weight loss. The FDA has not approved Trulicity as a ...